Focus on limbal stem cell deficiency and limbal cell transplantation

Limbal stem cell deficiency(LSCD)causes severe vision impairment and can lead to blindness,representing one of the most challenging ocular surface disorders.Stem cell deficiency can be congenital or,more often,acquired.The categorization of ocular surface transplantation techniques is crucial to achieving treatment homogeneity and quality of care,according to the anatomic source of the tissue being transplanted,genetic source,autologous or allogenic transplantation(to reflect histocompatibility in the latter group),and cell culture and tissue engineering techniques.The aim of this minireview is to provide a summary of the management of LSCD,from clinical characteristics and therapeutic outcomes to the development of novel therapeutic approaches.The manuscript also briefly summarizes recent findings in the current literature and outlines the future challenges to overcome in the management of the major types of ocular surface failure.

Cell-based therapies for limbal stem cell deficiency: a literature review

Background and Objective:Limbal stem cell deficiency(LSCD)is characterized by the insufficiency of limbal stem cells to maintain the corneal epithelium.Severe cases of LSCD may be treated with limbal transplantation from healthy autologous or allogeneic limbal tissue.Multiple cell-based therapies have been studied as alternative treatments to improve success rates and minimize immunosuppressive regimens after allogeneic transplants.In this review,we describe the success rates,and complications of different cell-based therapies for LSCD.We also discuss each therapy’s relative strengths and weaknesses,their history in animal and human studies,and their effectiveness compared to traditional transplants.Methods:PubMed was searched for publications using the terms LSCD,cell-based therapy,cultivated limbal epithelial transplantation(CLET),cultivated oral mucosal epithelial transplantation(COMET),and mesenchymal stem cells from 1989 to August 2022.Inclusion criteria were English language articles.Exclusion criteria were non-English language articles.Key Content and Findings:current cell-based therapies for LSCD are CLET and non-limbal epithelial cells.Non-limbal epithelial cell methods include COMET,conjunctival epithelial autografts,and mesenchymal stem/stromal cells(MSCs).Moreover,several alternative potential sources of non-limbal cells have described,including induced pluripotent stem cells(iPSCs),human embryonic stem cells(hESCs),human dental pulp stem cells,hair follicle bulge-derived epithelial stem cells,amniotic membrane epithelial cells,and human umbilical cord lining epithelial cells.Conclusions:Cell-based therapies are a promising treatment modality for LSCD.While CLET is currently the only approved cell-based therapy and is only approved in the European Union,more novel methods have also been shown to be effective in human or animal studies thus far.Non-limbal epithelial cells such as COMET are also an alternative treatment to allogeneic transplants especially as a surface stabilizing procedure.iPSCs are currently being studied in early phase trials and have the potential to revolutionize the way LSCD is treated.Lastly,cell-based therapies for restoring the limbal niche such as mesenchymal stem cells have also shown promising results in the first human proof-of-concept study.Several potential sources of non-limbal cells are under investigation.

Chronic ocular GVHD:limbal and conjunctival stem cell allografts from the same hematopoietic stem cell donor

Dear Editor,I am Dr.Elias F Jarade from the Beirut Eye and ENT Specialist Hospital, Beirut, Lebanon. I write to describe a novel surgical technique in the management of chronic ocular graft-versus-host disease（GVHD）.

Midterm outcomes of penetrating keratoplasty following allogeneic cultivated limbal epithelial transplantation in patients with bilateral limbal stem cell deficiency

AIM:To evaluate the midterm outcomes of penetrating keratoplasty(PK)following allogeneic cultivated limbal epithelial transplantation(CLET)for bilateral total limbal stem cell deficiency(LSCD).METHODS:Ten patients(10 eyes)with bilateral LSCD were enrolled in this prospective noncomparative case series study.Each participant underwent PK approximately 6 mo after a CLET.Topical tacrolimus,topical and systemic steroids,and oral ciclosporin were administered postoperatively.Best-corrected visual acuity(BCVA),intraocular pressure(IOP),ocular surface grading scores(OSS),corneal graft epithelial rehabilitation,persistent epithelial defect(PED),immunological rejection,and graft survival rate were assessed.RESULTS:The time interval between PK and allogeneic CLET was 6.90±1.29(6-10)mo.BCVA improved from 2.46±0.32 log MAR preoperatively to 0.77±0.55 log MAR post-PK(P<0.001).Kaplan-Meier analysis of mean graft survival revealed graft survival rates of 100%at 12 and 24 mo and 80.0%at 36 mo.PEDs appeared in 5 eyes at different periods post-PK,and graft rejection occurred in 4 eyes.The total OSS decreased from 12.4±4.4 before allogeneic CLET to 1.4±1.51 after PK.CONCLUSION:A sequential therapy design of PK following allogeneic CLET can maintain a stable ocular surface with improved BCVA despite the relatively high graft rejection rate.

Limbal epithelial stem cells in corneal surface reconstruction

Cornea serves as the partial front barrier and major light reflection organ of the eye.The integrity of corneal surface is essential for ocular function.Injuries or congenital diseases could significantly destruct the homeostasis of the ocular surface,especially the microenvironment of limbal epithelial stem cells(LESCs),and will eventually cause dysfunction of corneal regeneration and diminish of LESCs.The loss of LESCs by different reasons are named limbal stem cell deficiency(LSCD),which is one of the leading cause of vision loss worldwide.To restore the corneal surface,LESC transplantation in the form of tissue or cell cultures is currently a viable and promising method to treat LSCD.In this review,we aim to introduce the characters and niche of LESCs,and discuss different aspects of its application in cornea surface reconstruction.

Corneal stem cells and tissue engineering: Current advances and future perspectives

Major advances are currently being made in regenerative medicine for cornea. Stem cell-based therapies represent a novel strategy that may substitute conventional corneal transplantation, albeit there aremany challenges ahead given the singularities of each cellular layer of the cornea. This review recapitulates the current data on corneal epithelial stem cells, corneal stromal stem cells and corneal endothelial cell progenitors. Corneal limbal autografts containing epithelial stem cells have been transplanted in humans for more than 20 years with great successful rates, and researchers now focus on ex vivo cultures and other cell lineages to transplant to the ocular surface. A small population of cells in the corneal endothelium was recently reported to have self-renewal capacity, although they do not proliferate in vivo. Two main obstacles have hindered endothelial cell transplantation to date: culture protocols and cell delivery methods to the posterior cornea in vivo. Human corneal stromal stem cells have been identified shortly after the recognition of precursors of endothelial cells. Stromal stem cells may have the potential to provide a direct cell-based therapeutic approach when injected to corneal scars. Furthermore, they exhibit the ability to deposit organized connective tissue in vitro and may be useful in corneal stroma engineering in the future. Recent advances and future perspectives in the field are discussed.

手术切除联合角膜缘干细胞移植治疗翼状胬肉的疗效观察

目的 观察手术切除联合角膜缘干细胞移植治疗翼状胬肉的疗效。方法 招募2020年1月至2022年12月启东市中医院收治的翼状胬肉患者180例,采用随机数字表法将其分为Ologen胶原基质植入组(接受手术切除联合Ologen胶原基质植入治疗,90例145眼)和角膜缘干细胞移植组(接受手术切除联合角膜缘干细胞移植治疗,90例147眼)。比较两组治疗后屈光状态、泪膜功能、舒适度情况、创面愈合时间、临床疗效及复发情况。结果 两组术后裸眼视力(UCVA)、泪膜破裂时间(BUT)呈上升趋势,角膜散光度(CA)呈下降趋势,两组变化幅度差异有统计学意义(P<0.05)。在术后6个月,Ologen胶原基质植入组UCVA、BUT低于角膜缘干细胞移植组,CA高于角膜缘干细胞移植组,差异有统计学意义(P<0.05)。术后6个月,在畏光流泪、异物感、眼痛、球结膜充血4个维度,角膜缘干细胞移植组的舒适度评分显著优于Ologen胶原基质植入组(P<0.05)。角膜缘干细胞移植组的创面愈合时间显著快于Ologen胶原基质植入组[(2.85±1.06)d vs (3.04±0.31)d;t=2.073,P=0.039]。角膜缘干细胞移植组的临床有效率显著高于Ologen胶原基质植入组(98.64%vs 93.10%;χ^(2)=5.678,P=0.017),术后6个月的复发率更低(0.00%vs 4.14%;χ^(2)=4.325,P=0.038)。结论 手术切除联合角膜缘干细胞移植治疗翼状胬肉的疗效优于手术切除联合Ologen胶原基质植入治疗,值得推荐。

低温等离子手术系统在翼状胬肉切除术中应用疗效研究

目的 探讨低温等离子手术系统在翼状胬肉切除联合角膜缘干细胞自体结膜移植术中的应用和临床效果。方法 回顾性分析自2020年3月至2022年3月常州市第三人民医院眼科接受手术治疗的46例(54眼)原发性翼状胬肉患者临床资料,手术方式均为翼状胬肉切除联合带角膜缘干细胞的自体结膜移植术,术中应用低温等离子手术系统进行胬肉头部切除及止血。记录术后角膜上皮愈合时间;术前及术后1、3、6、12个月的最佳矫正视力(BCVA)、泪液分泌试验(SIT)、泪膜破裂时间(BUT)、泪河高度;术后并发症及复发率。结果 术后1周,所有患者角膜上皮均愈合,愈合时间(5.7±1.0)d。术后各时间点的BCVA均较术前改善,且术后3、6、12个月的BCVA较术后1个月明显改善,差异有统计学意义(P<0.05)。术后3、6、12个月的BCVA比较,差异无统计学意义(P>0.05)。术后各时间点的SIT、BUT、泪河高度均较术前提高,且术后1、3、6、12个月的SIT、BUT、泪河高度逐渐升高,各时间点比较,差异均有统计学意义(P<0.05)。1例患者于术后2周出现结膜瓣坏死、巩膜溶解现象,经积极的羊膜移植术治疗后得到治愈。患者术后均未出现复发,有2例患者分别在术后3个月和6个月切除区出现增生纤维组织,但尚未侵及透明角膜。结论 翼状胬肉切除联合带角膜缘干细胞的自体结膜移植术有利于改善患者术后视力、促进泪膜功能恢复和减少角膜上皮愈合时间,且复发率低。低温等离子射频消融术在翼状胬肉切除术中,可达到组织切割、止血的双重作用,并减轻术中对组织的损伤,有利于术后眼表环境的修复和重建。

不同方法及术后干预对翼状胬肉患者舒适度及疗效的影响

目的:探讨不同球结膜移植术及术后干预对翼状胬肉患者舒适度及疗效的影响。方法:选取2017年1月—2019年12月样本医院收治的200例(200眼)翼状胬肉患者作为研究对象,按随机数表法分为A、B、C、D 4组,每组50例(50眼)。A、B组采用切除术联合自体游离结膜瓣移植术,C、D组采用切除术联合角膜缘干细胞移植,B、D组术后佩戴角膜绷带镜。观察对比4组患者术后眼部不适、视力、角膜上皮愈合时间、治愈率及复发率情况。结果:4组患者术后均出现不同程度的眼部不适,3 d后缓解,2周后基本消失。术后1 d、3 d、7 d B组患者眼部不适较A组轻,D组患者眼部不适较C组轻,而A组与C组、B组与D组之间比较,差异无统计学意义(F=0.083,P>0.05);术后1 d、3 d 4组患者的裸眼视力均有不同程度的下降。术后1 d、3 d B组患者视力较A组高,D组患者视力较C组高,差异有统计学意义(F=3.026、3.088,P<0.05);4组患者术后角膜上皮愈合约需4~6 d,B组角膜上皮愈合时间较A组短,D组较C组短,差异有统计学意义(F=35.800,P<0.05);4组患者术后治愈率和术后翼状胬肉复发情况比较,差异无统计学意义(χ^(2)=0.632、1.031,P>0.05)。结论:切除术联合角膜缘干细胞移植对翼状胬肉患者治疗效果显著,复发率较低。佩戴角膜绷带镜可减轻术后眼部不适,有利于角膜上皮愈合和早期视力的稳定,对翼状胬肉的治疗具有积极意义。

角膜缘干细胞移植术联合翼状胬肉切除术对翼状胬肉患者的临床效果

目的探讨临床治疗翼状胬肉疾病采用角膜缘干细胞移植术、翼状胬肉切除术联合方式的效果。方法选择2016年3月1日至2019年9月30日常州市第七人民医院眼科收诊治疗的翼状胬肉患者98例进行研究,按照随机数表法分为两组,对照组(49例)单纯采用翼状胬肉切除术治疗;观察组(49例)在对照组基础上联合角膜缘干细胞移植术治疗。比较两组治疗效果,分别记录各组患者治疗所用时间,比较组间差异性。观察两组患者术后产生的并发症表现,统计比较总发生率。结果观察组翼状胬肉患者经联合术式治疗后,总有效率明显高于对照组,疾病复发率低于对照组,差异有统计学意义(P<0.05)。观察组创口愈合及住院治疗总时间均低于对照组,差异有统计学意义(P<0.05)。观察组术后产生的创面水肿等并发症总发生率低于对照组,差异有统计学意义(P<0.05)。结论临床治疗翼状胬肉可在翼状胬肉切除术基础上联用角膜缘干细胞移植术式,相比单纯切除治疗效果更佳,术后患者复发率更低且并发症少,值得运用推广。

切除联合自体角膜缘干细胞移植术治疗原发性翼状胬肉的研究

目的探讨翼状胬肉切除联合自体角膜缘干细胞移植术治疗原发性翼状胬肉的临床效果及安全性。方法回顾性研究2019年1月至2023年1月在本院接受原发性翼状胬肉手术治疗的66例患者病历资料,将66例患者根据手术方式的不同分为对照组(n=33,翼状胬肉切除联合游离结膜瓣移植术)及试验组(n=33,翼状胬肉切除联合自体角膜缘干细胞移植术)。比较两组临床效果、术后结膜瓣愈合时间、角膜上皮修复时间,记录术前及术后1个月、3个月、6个月泪膜破裂时间(TBUT)变化及术后并发症发生率和术后6个月的复发率。结果试验组患者治疗后的临床疗效高于对照组,术后结膜瓣愈合时间、角膜上皮修复时间明显短于对照组,术后的1月、3月、6月时TBUT时间明显长于对照组(P<0.05);两组术后并发症的发生率及复发率比较,差异无统计学意义(P>0.05)。结论翼状胬肉切除联合自体角膜缘干细胞移植术治疗原发性翼状胬肉具有良好的治疗效果和安全性,可降低术后复发率,且不增加术后并发症发生率。

翼状胬肉切除术联合角膜缘干细胞移植术后应用角膜绷带镜的效果

目的:分析翼状胬肉切除术联合角膜缘干细胞移植术后应用角膜绷带镜的效果。方法:选取2017年1月—2022年12月于双桥医院眼整形科行翼状胬肉切除术联合角膜缘干细胞移植术患者80例(80眼)作为研究对象,随机分为对照组和观察组,各40例。对照组术后应用妥布霉素地塞米松滴眼液、玻璃酸钠滴眼液,观察组在对照组基础上应用角膜绷带镜。比较两组恢复效果。结果:观察组复发率低于对照组,角膜上皮修复时间短于对照组,差异有统计学意义(P<0.05)。术后1 d,两组疼痛评分比较,差异无统计学意义(P>0.05);术后3 d,两组疼痛评分均低于术后1 d,观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组症状评分比较,差异无统计学意义(P>0.05);治疗后,观察组畏光、异物感、流泪、眼部充血评分低于对照组,差异均有统计学意义(P<0.05)。结论:角膜绷带镜有利于减轻患者术后疼痛,缓解术后症状,降低复发率。

除风益损汤加减方对翼状胬肉术后眼表损伤修复的作用探究

目的:探讨除风益损汤加减方对翼状胬肉术后眼表损伤修复的影响。方法:纳入研究的100例原发性翼状胬肉患者随机分为观察组和对照组,各50例。2组均接受翼状胬肉切除联合角膜缘干细胞移植手术,其中对照组术后采用常规滴眼液点眼治疗,观察组在对照组的基础上联合口服除风益损汤加减方治疗,用药1周。比较2组术后眼部疼痛评分、眼部体征、泪膜破裂时间、角膜状态及复发率的差异。结果:术后1日、2日、1周2组眼部疼痛评分均优于术后6h,差异均有统计学意义;观察组眼部疼痛评分评分优于对照组,差异有统计学意义;术后2日、1周2组眼部体征积分均优于术后1日,差异均有统计学意义;观察组眼部体征积分优于对照组,差异有统计学意义;术后1周观察组泪膜破裂时间及角膜状态评分均优于对照组,差异均有统计学意义;术后随访6个月,观察组复发率低于对照组,差异有统计学意义。结论:除风益损汤加减方可促进翼状胬肉切除联合角膜缘干细胞移植术后眼表损伤的修复。

自体结膜瓣移植在原发性翼状胬肉治疗中的疗效分析

目的探讨自体结膜瓣移植在原发性翼状胬肉治疗中的治疗效果。方法选取120例患有原发性翼状胬肉的患者作为研究对象,随机将其分成观察组(n=60)和对照组(n=60)。两组患者均实施胬肉切除术。对照组患者给予角膜缘干细胞移植手术治疗,观察组患者采用自体结膜瓣移植治疗。对比两组患者治疗后的舒适度。结果观察组患者治疗后惧光、流泪、异物感、眼痛不适、视力不良评分分别为(1.23±0.12)、(0.15±0.07)、(1.54±0.21)、(0.55±0.05)、(0.65±0.14)分,明显低于对照组的(2.01±0.15)、(1.04±0.05)、(1.98±0.11)、(1.75±0.09)、(1.87±0.12)分(P<0.05)。结论自体结膜瓣移植联合胬肉切除术治疗原发性翼状胬肉有显著效果,能提升患者治疗后的舒适度,值得临床推广应用。

Medical and surgical approach to ocular surface reconstruction

Ocular surface disease(OSD)can have a severe impact on patients as it can lead to visual impairment and persistent discomfort.Ocular surface reconstruction(OSR)is an approach to the management of ocular diseases that cause structural damage to the ocular surface.OSR encompasses both medical and surgical treatment options.In this review,we discuss the medical and surgical strategies used in OSR.Medical management often aims to treat tear insufficiency,inflammation,and keratinization.Surgical treatments may be employed for a variety of reasons,including failure of medical management.This may include improving the oculo-palpebral structures in order to improve lid positioning and tear film.Additional therapies focus on improving tear production,such as through salivary gland transplantation.In situations where the ocular surface is so severely damaged that there is loss of limbal stem cells,limbal stem cell transplant(LSCT)may be indicated.Other surgeries such as amniotic membrane transplant(AMT)and conjunctival flaps(CFs)can help promote corneal healing.Finally,in severe situations where the cornea is beyond salvage,corneal transplantation,such as a penetrating keratoplasty(PKP),can be considered.OSR often requires a combination of medical and surgical approaches targeted to each specific patient’s presentation in order to achieve optimal outcomes.

翼状胬肉切除与角膜缘干细胞移植联合治疗对翼状胬肉患者角膜散光及视力的影响

目的:探究翼状胬肉切除联合角膜缘干细胞移植对翼状胬肉患者的影响。方法:选取2020年3月—2023年3月镇江市第四人民医院收治的100例翼状胬肉患者作为研究对象,按随机数表法分为两组,各50例。对照组行翼状胬肉切除治疗,观察组在对照组基础上加用角膜缘干细胞移植治疗。比较两组临床疗效、拆线时间、角膜上皮修复时间、视力恢复情况、泪膜功能及并发症发生情况。结果:观察组治疗总有效率高于对照组,拆线时间、角膜上皮修复时间早于对照组,并发症总发生率低于对照组,差异有统计学意义(P<0.05)。术后3个月,观察组最佳矫正视力(BCVA)、角膜水平曲度、角膜垂直曲度高于对照组,角膜散光度低于对照组,泪膜破裂时间(BUT)、泪液分泌试验(SⅠT)长于对照组,差异有统计学意义(P<0.05)。结论:翼状胬肉切除联合角膜缘干细胞移植可修复翼状胬肉患者角膜上皮,改善视力,有利于泪膜功能的提升,且并发症少。

自体角膜缘干细胞移植术对翼状胬肉患者术后创面愈合及预后的影响

目的探讨自体角膜缘干细胞移植术对翼状胬肉患者术后创面愈合及预后的影响。方法将72例翼状胬肉患者随机分为两组,均采用翼状胬肉切除术治疗。对照组采用羊膜移植术治疗,观察组采用自体角膜缘干细胞移植术治疗。比较两组的治疗效果、创面愈合时间、视力水平、不良事件发生率与复发率。结果观察组治疗总有效率高于对照组,创面愈合时间短于对照组,治疗后3个月的不良事件发生率和复发率低于对照组(P<0.05)。结论自体角膜缘干细胞移植术治疗翼状胬肉的效果较好,可缩短患者愈合时间,改善其视力水平,且安全性较高,复发风险较低。

老年翼状胬肉患者翼状胬肉切除与角膜缘干细胞移植联合治疗的疗效分析

目的分析翼状胬肉切除联合角膜缘干细胞移植的临床疗效。方法回顾性选取2021年1月—2023年1月尤溪县总医院收治的80例老年翼状胬肉患者的临床资料,40例采用单纯翼状胬肉切除术治疗患者作为对照组,40例加用角膜缘干细胞移植治疗患者作为观察组。比较两组治疗效果。结果治疗后,观察组泪膜破裂时间、基础泪液分泌测定高于对照组,角结膜荧光素染色评分低于对照组,差异有统计学意义(P均<0.05)。治疗后3、7 d,观察组结膜水肿、结膜充血评分低于对照组,差异有统计学意义(P均<0.05)。观察组视觉功能指标改善优于对照组,差异有统计学意义(P<0.05)。观察组并发症发生率为12.50%,复发率为5.00%,低于对照组,差异有统计学意义(χ^(2)=4.588、5.165,P均<0.05)。结论翼状胬肉切除联合角膜缘干细胞移植可有效改善老年翼状胬肉患者泪膜稳定性和视觉功能,降低并发症发生率及复发率。

翼状胬肉切除联合角膜缘干细胞移植术治疗翼状胬肉的临床效果探讨

目的探讨翼状胬肉切除联合角膜缘干细胞移植(Corneal Limbal Stem Cell Transplantation,CAT)术治疗翼状胬肉的临床效果。方法随机选取2022年12月—2023年10月新疆伊宁市农四师医院收治的60例翼状胬肉患者作为研究对象,采用随机数表法分为两组。对照组(30例)行翼状胬肉切除+自体结膜瓣缘干细胞移植术(Autologous Conjunctival Flap Stem Cell Transplantation,LCAT)处理,观察组(30例)行翼状胬肉切除+CAT术处理。对比两组的泪膜功能[泪膜破裂时间(Break-up Time,BUT)、泪液分泌试验(Schirmer Test,SIT)]、视力水平[裸眼视力(Naked Vision,UCVA)、角膜屈光度]以及术后并发症发生状况。结果术后3个月,两组的BUT与SIT泪膜功能指标均高于术前,但组间对比,差异无统计学意义(P均>0.05)。术后3个月,两组UCVA值高于术前,角膜屈光度小于术前,但组间对比,差异无统计学意义(P均>0.05)。观察组与对照组术后并发症发生率对比(10.00%vs 6.67%),差异无统计学意义(P>0.05)。结论翼状胬肉切除+CAT术式用于翼状胬肉患者的处理,其安全性、视力及泪膜功能改善效果与翼状胬肉切除+LCAT术式相当。

生物羊膜覆盖联合自体角膜缘干细胞移植在翼状胬肉切除术患者中的应用效果

目的:观察生物羊膜覆盖联合自体角膜缘干细胞移植在翼状胬肉切除术患者中的应用效果。方法:选取2021年1月至2024年2月该院收治的76例翼状胬肉患者进行前瞻性研究,按照随机信封法将其分为研究组与对照组各38例。对照组应用自体角膜缘干细胞移植联合翼状胬肉切除术治疗,研究组在对照组基础上联合生物羊膜覆盖治疗,比较两组痊愈率、复发率、临床相关指标(角膜上皮修复时间、拆线时间)水平,手术前后视力水平、散光指标[角膜散光度、表面不对称指数(SAI)]水平、泪液炎性因子[白细胞介素-6(IL-6)、白细胞介素-2(IL-2)]水平,以及术后3个月并发症发生率。结果:研究组痊愈率为94.74%(36/38),高于对照组的78.95%(30/38),差异有统计学意义(P<0.05);两组复发率比较,差异无统计学意义(P>0.05);研究组角膜上皮修复时间、拆线时间均短于对照组,差异有统计学意义(P<0.05);术后3个月,研究组视力水平高于对照组,角膜散光度、SAI水平均低于对照组,差异有统计学意义(P<0.05);术后7 d,研究组泪液IL-6、IL-2水平均低于对照组,差异有统计学意义(P<0.05);两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:生物羊膜覆盖联合自体角膜缘干细胞移植应用于翼状胬肉切除术患者可提高痊愈率和视力水平,改善临床相关指标水平,降低散光指标和泪液炎性因子水平,效果优于单纯自体角膜缘干细胞移植联合翼状胬肉切除术治疗。